tbuckley/cabot-search huggingface dataset:
Clinical grand rounds. Hemochromatosis (iron-storage disease)
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SUICIDE—A LEADING CAUSE OF DEATH
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Watchman
Authors: Richard B. Weinberg
Journal: Annals of Internal Medicine (2012)

On Being a Doctor17 April 2012The WatchmanRichard B. Weinberg, MDRichard B. Weinberg, MDFrom Wake Forest School of Medicine, Winston-Salem, NC 27157.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-8-201204170-00013 Audio Reading - “The Watchman” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Watchman," by R.B. Weinberg Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail “I have a very big favor to ask you.”Most members of my synagogue had heard, at one time or another, the unmistakable voice of Rachel Rosen at the other end of the phone. For almost any organized activity—a Sunday school picnic, a charity drive, a reception for a new family, an evening lecture by a visiting scholar—“Rachel the Arranger” could be found working behind the scenes, making sure the event went off perfectly.I immediately began to compose my regrets. This was not a good time for big favors. My children were out of school for the summer, my ... Author, Article, and Disclosure InformationAffiliations: From Wake Forest School of Medicine, Winston-Salem, NC 27157.Corresponding Author: Richard B. Weinberg, MD, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “The Watchman” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "The Watchman," by R.B. Weinberg Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 April 2012Volume 156, Issue 8Page: 602-603KeywordsChildrenEmotionsHeartMouthMyocardial infarctionNursesSleepStormsTouchVital signs ePublished: 17 April 2012 Issue Published: 17 April 2012 CopyrightCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Tetracycline
Authors: Robert S. Bart
Journal: JAMA (1976)

<h3>To the Editor.—</h3> I am writing in reference to the commentary entitled "The Treatment of Amebiasis: A Recurrent Agony," by B. H. Kean, MD (235:501, 1976). In his discussion, the author states that "tetracycline, originally advocated at a dosage of 2 gm daily for 14 days, cannot be used at that level without considerable toxic reaction, and a dosage of 1 gm daily for seven days is hardly curative." I do not wish to get involved in a discussion of the treatment of amebiasis, since my experience in treating that disease is so limited that I cannot speak with any authority on the subject. However, it would seem inappropriate to abandon the use of tetracycline, in the dosage of 2 gm/day for 14 days, solely on the grounds that it is too toxic. Baer and co-workers (<i>Arch Dermatol</i>105:608, 1972) have treated severe conglobate acne with doses of 2 gm/day
Current Status of Studies Concerned with Evaluation of Toxic Effects of Chemicals on the Testes
Authors: Emil Steinberger
Journal: Environmental Health Perspectives (1981)

A brief review of the history of the subject is provided. An attempt is made to define the current status of the knowledge and the reasons why our knowledge in this area of science is poor. The information gained from studies employing lower species is contrasted with information on the human male. The most commonly utilized techniques for evaluating the effects of toxic agents on the male reproductive system is briefly summarized. The growth of knowledge in physiology, biochemistry, and hormonal control of testicular function during the past ten to fifteen years is discussed; and, the specific most pertinant advances are noted. The difficulties in utilizing the human subject for toxicologic studies are pointed out and the reasons why the knowledge of the effect of toxic agents on the human testes are meager are discussed. The methodology utilized for the study of the functional integrity of the human testes and the specific parameters widely utilized for this purpose are discussed and criticized. The fact that it is extremely difficult to evaluate changes in the testicular function of men are emphasized and the extremely wide variability is pointed out. Furthermore, it is demonstrated that at this moment, we are lacking some of the most fundamental information concerning the normal function of the human testes; and, that there is a poor understanding of parameters of "normalcy". The three parameters used most commonly to define normalcy of human testes, namely, testicular histology, sperm output, and hormonal levels are discussed and the difficulties and pitfalls of these measurements are pointed out.
Add exercise to calcium in osteoporosis prevention
Authors: M. Korcok
Journal: JAMA (1982)

Dietary calcium supplements can provide valuable aid in slowing age-related bone loss and warding off some of the hazards of osteoporosis. But taking supplements without engaging in physical exercise— preferably of the jogging or walking variety—is like settling for half a loaf. As was agreed at a recent symposium on diet and exercise held in Orlando, Fla, under the auspices of the Florida Medical Association and the American Medical Association, the mechanisms of action of dietary calcium supplementation and physical activity appear to be different. Calcium acts to suppress bone resorption, whereas mechanical stress seems to enhance bone formation. Consequently, combining the two measures appears to be the most practical approach to preserving sound skeletal mass into old age. In one report on the subject, G. Donald Whedon, MD, senior science advisor to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, told of several studies showing that
Association of American Medical Colleges and American Medical Association joint statement on physician workforce planning and graduate medical education reform policies
Authors: J. J. Cohen
Journal: JAMA (1994)

THE Association of American Medical Colleges (AAMC) and the American Medical Association (AMA) recognize that there are a number of policy issues related to the size and specialty mix of the physician workforce and the organization and funding of graduate medical education (GME) and the academic environment that must be addressed on an ongoing basis to further the health of the public and respond to the goals and requirements of health system reform. Both associations concur with the need for a better balance between generalist physicians and nongeneralist specialty physicians and are concerned that the size of the future physician workforce may exceed both the public's need and the demand for physicians' services. Both associations also concur that planned changes in the size or specialty mix of the workforce must be approached thoughtfully and deliberately. The AMA and AAMC offer the following principles to guide these deliberations. A national physician
Some recollections of the meningococcal diseases. The first Harry F. Dowling lecture
Authors: H. A. Feldman
Journal: JAMA (1972)

I would be less than truthful were I to deny that I approached this assignment with anything but considerable trepidation. For one, this being the first Harry F. Dowling Lecture means that it should set the tone for those which follow. That Harry Dowling is here makes the occasion truly enjoyable but unavoidably adds to the usual anxieties of the student who wishes to perform well in the presence of his teacher. In our case, this relationship covers a span of almost 35 years. Should I succumb to the temptation to "tell it like it was" by substituting reminiscence for fact, then perhaps you will be charitable and will seek and find some purpose in such deviations. I first met Harry Dowling in 1936. At that time, I was a medical student at the George Washington University School of Medicine, working in John Hanks's laboratory in the department of bacteriology.
Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped
Authors: G. B. Forbes
Journal: JAMA (1992)

<h3>Objective.</h3> —To study the changes in body composition produced by large doses of testosterone and reversal of changes when the drug is discontinued. <h3>Design.</h3> —Weekly injections of testosterone enanthate were given to young adult male volunteers for 12 weeks. Repeated assays of lean body mass (LBM) by potassium 40 counting were made during this period and at intervals during the ensuing 5 to 6 months. <h3>Participants and Setting.</h3> —Subjects who were living on their own, who were known to be free of significant disease, and who volunteered as controls for a study of patients with neuromuscular disease. Assays were done in the Clinical Research Center. <h3>Main Outcome Measures.</h3> —Changes in body weight, LBM, and (by subtraction) body fat. <h3>Results.</h3> —Testosterone treatment produced a progressive increase in LBM and a progressive decrease in body fat. Body composition reverted slowly toward normal when the injections were stopped; thus, the effects of testosterone lingered for some time. The magnitude of the observed changes in LBM was in keeping with the change in urinary creatinine excretion reported for these same subjects. <h3>Conclusion.</h3> —Testosterone is a powerful anabolic agent that also serves to reduce body fat content. (<i>JAMA</i>. 1992;267:397-399)
Renal vein valve
Authors: P. T. McDonald
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The health care of Hispanics
Journal: JAMA (1991)

<h3>To the Editor.—</h3> The January 9, 1991, issue of<i>JAMA</i>contains several articles relating to health care among "Hispanics." I would like the authors to define what they mean by Hispanics. "Hispanic" is neither a race nor a definite group of people. The word<i>Hispanic</i>presumably refers to Spain, although the articles deal with Latin American immigrants. I have a very difficult time understanding who a Hispanic is supposed to be and why these people are grouped together. I see no similarity whatsoever from the racial, biological, cultural, or linguistic point of view among these populations. I am well aware of the fact that<i>Hispanic</i>is a word found in many application forms, statistical analyses, etc, but I was never able to understand what this means. I would like to ask the authors of these articles to explain the similarities between an Argentinian of Italian descent, a Bolivian of Indian
Book Review Surgery of the Heart . By E. S. J. King, M.D., M.S., D.Sc. (Melb.), F.R.C.S. (Eng.), F.R.A.C.S., Major A.A.M.C. 8°, cloth, 728 pp., with 4 plates and 268 illustrations. Baltimore: Williams and Wilkins Company, 1941. $13.50.
Journal: New England Journal of Medicine (1942)
Collateral Lethality in Pancreatic Cancer
Journal: Cancer Discovery (2017)

The chromosome 18q21 deletion in nearly one third of pancreatic adenocarcinomas eliminates not only the tumor suppressor SMAD4, but also neighboring genes with important cellular roles, such as ME2 This is tolerated by cancer cells only because ME2 has a functionally redundant paralog, ME3, elsewhere in the genome. A study shows that these cells are vulnerable to ME3 silencing; this concept of collateral lethality could provide a new therapeutic strategy for a difficult-to-treat disease.
Abstracts
Journal: Neuro-Oncology (2001)

Background: Depending on dose, dexamethasone has been known to inhibit or stimulate growth of 9L gliosarcoma.It has been shown that dexamethasone decreases VEGF expression in 9L gliosarcoma.It remains to be determined whether dexamethasone has an effect on other angiogenic factors (Ang1/Ang2/PLGF).We demonstrate, by using MRI-rCB V and histologic analysis, that dexamethasone decreases rCBV and vessel diameter in Fischer rats intra-cranially inoculated with 9L gliosarcoma.Method: Three groups of seven male Fischer rats each, were anesthetized, immobilized and inoculated with 105 9L gliosarcoma tumor cells 1mm anterior and 2mm lateral to bregma on the right side of the head.Group 2 was excluded due to inadequate tumor implantation.Half of the rats were treated 10 days after tumor implantation with 3mg/kg of dexamethasone over 4 days to approximate clinically relevant doses.MR imaging was obtained on 3 Tesla scanner 14 days after tumor implantation.All MRI derived tumor rCBV data, from region of interest (ROI) cursors, were normalized to contralateral normal brain.Gradient echo (GE) and spin echo (SE) rCBV maps were created to demonstrate total vasculature (GE) and microvasculature (SE).MRI/rCBV/GE/SE techniques were validated by us and others (1,2).After MRI studies were performed, rat circulation was perfused with Microfil in 7 of 14 rats and brains were sectioned into 50 µm slices.A computer analysis method was used to determine vessel diameter and fractional blood volume (fv) in tumors.Results: Using post-contrast T1-weighted images and GE rCBV maps, both groups 1 and 3 of dexamethasone treated rats showed 67% and 47% decrease in area of enhancement as compared to untreated rats, respectively (p=0.005;p=0.009).Due to small sample size, uncorrected GE rCBV maps for contrast extravasation treated and untreated groups did not show a statistically significant difference though there was a qualitative difference between groups.In groups 3, rCBV maps agreed with fv as per histologic analysis (p=0.001).In contrast to GE, SE rCBV showed a significant increase in blood volume in treated rats.Histologic analysis showed that in steroid treated rat, tumors vessel diameter was 49.9% that of untreated rats (p=0.001).Conclusion: RCBV techniques, GE/SE, correlated with histologic analysis and validate rCBV as a non-invasive measure of blood volume and vessel diameter.The increase in microvascular blood volume in treated rats suggests that dexamethasone may affect expression of angiogenic factors differently depending on vessel size or diameter.Ongoing studies will assess how dexamethasone effects expression of Angiopoietin 1, Angiopoietin 2, VEGF and PLGF. 1.
Potential Impact of Health System Reform on Medical Education
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene expression profiling (GEP) for the prediction of response to neoadjuvant paclitaxel and gemcitabine in breast cancer (BC). Preliminary results from a Phase II trial
Authors: A. Llombart-Cussac, G. Moreno-Bueno, A. Ruiz, J. Albanell, J. I. Mayordomo, V. Carñana, V. Guillem, R. Diaz-Uriarte, J. Palacios, I. Garcia-Ribas
Journal: Journal of Clinical Oncology (2004)

580 Background: GEP of primary breast tumors can be useful in selecting specific chemotherapy regimens based on their probabilities of response. Methods: A neoadjuvant phase II trial for stage II-III BC patients was prospectively designed to test the ability of GEP to predict clinical and pathological responses. Treatment schedule consisted of 6 cycles of both G 2,500 mg/m2 and T 150 mg/m2 on day 1 of a 14 day-cycle before surgery. All 70 patients are already recruited. Mean age 50 yr (range, 26–71), and tumor size: 35 mm (range; 23–100). The analysis of GEP was performed with amplified-RNA from frozen tru-cut biopsies hybridized against a Universal Human Reference RNA pool. GEP analysis was performed in duplicate in 70% of the samples with a correlation coefficient of 0.95 (CNIO Oncochip is a cDNA array comprising 9,300 cancer-related genes: http://bioinfo.cnio.es/data/oncochip/). The analysis of predictor genes was performed using the Random Forests method. To validate the genes in the predictor gene set, RT PCR was applied to 10% of the genes and all analyzed samples. Results: At present, 36 patients had completed chemotherapy [clinical response: 13 CR, 20 PR and 3 SD] and undergone surgery [5 pCR, another 5 with microscopic foci (<1mm) and 26 non-responders]. We have analyzed the GEP and cross-validated the predictive performance for the first 28 cases. The highest error rate occurs during classification of the sensitive tumors: about 30 to 40% with clinical response and 35 to 55% with pathological response (considering pathological complete and microscopic foci as single class) are misclassified. However, for resistant tumors, we obtained a correct classification with an accuracy of 91% regarding both clinical and pathological response. Some of the predictor genes are involved in drug metabolism, DNA biosynthesis, and extracellular matrix remodeling. Conclusions: GT is clinically effective regimen for neoadjuvant BC treatment. GEP analysis is a reliable tool for pre-treatment prediction of non-responding patients who could benefit from other chemotherapy regimens. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly & Co.
Announcement Regarding Availability of Funds for Research on Lymphatic Leukemia
Journal: JNCI Journal of the National Cancer Institute (1949)

Announcement Regarding Availability of Funds for Research on Lymphatic Leukemia Get access JNCI: Journal of the National Cancer Institute, Volume 10, Issue 1, August 1949, Page 223, https://doi.org/10.1093/jnci/10.1.223 Published: 01 August 1949